TO THE EDITOR-Infectious diseases specialists face a challenging era highlighted by multidrug-resistant pathogens and antimicrobial resistance. These issues have fueled increasing emphasis on antimicrobial stewardship [1, 2] . Essential in antimicrobial stewardship is the practice of appropriate antibiotic use and avoidance of unnecessary antimicrobial agents. One such example is the often unnecessary double anaerobic coverage therapy [3] . In the setting of complicated intra-abdominal infections, data suggests that implementation of stewardship programs effectively reduces unnecessary antimicrobial use [4] .
The Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of complicated intraabdominal infections [5] thoroughly outline the appropriate use of antimicrobials for various diagnoses. However, some confusion arises upon further review. In Table 4 of the guidelines addressing initial empiric treatment of biliary infection in adults, except for mild-to-moderate, community-acquired cholecystitis, the recommendations for antimicrobial therapy are stated as "imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, levlofloxacin or cefepime, each in combination with metronidazole." The wording suggests the invariable addition of metronidazole to every antibiotic listed, even antibiotics with significant anaerobic activity such as carbapenems and extended spectrum penicillin-beta lactamase inhibitors. Recommendation 61 in the text adds further ambiguity by stating that "anaerobic therapy is not indicated unless a biliary-enteric anastamosis is present. (B-II)"
The IDSA guidelines specifically cite the "Tokyo Guidelines" in the Evidence Summary as references for antimicrobial therapeutic strategies that are used for cases of acute cholecystitis and cholangitis [6] [7] [8] [9] . However, a review of the Tokyo Guidelines for specific antimicrobial therapy recommendations for acute cholecystitis reveals that adjunctive metronidazole is only recommended in moderate and severe acute cholecystitis when paired with a fluoroquinolone "when anaerobic bacteria are detected or are expected to co-exist." The section of the Tokyo Guidelines that addresses antimicrobial therapy for acute cholangitis (which is not specifically referenced in the IDSA guidelines) lists adjunctive metronidazole as an option for moderate to severe cholangitis in combination with a third-or fourth-generation cephalosporin, aztreonam, or a fluoroquinolone. Carbapenems and "wide-spectrum penicillin/ β-lactamase inhibitors" (ie, ampicillinsulbactam and piperacillin-tazobactam) are listed as single-agent options.
Thus, in cases where anaerobic coverage is deemed appropriate, the Tokyo Guidelines seem to support a regimen consisting of a carbapenem or a beta-lactam/ beta-lactamase inhibitor. Either of these agents would already provide excellent anaerobic activity, and, hence, their combination with metronidazole would seem unnecessary in treating most biliary infections. In our view, the recommendations for antimicrobial therapy in the case of biliary infections in Table 4 of the IDSA guidelines may instead read as follows: "Imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam OR one of the following in combination with metronidazole: ciprofloxacin, levofloxacin, or cefepime." As we enter an age of antimicrobial stewardship where it is of the utmost importance to reduce any unnecessary antimicrobial use, we call on the authors of the IDSA guidelines to further clarify their recommendations on the role of adjunctive metronidazole in biliary infections. 
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